Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ambrx Biopharma Inc ADR (NY: AMAM )

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma Inc ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
From Ambrx, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee
From Ambrx, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Illumina (NASDAQ:ILMN) was the biggest company... 
Via Benzinga
Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial
Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low
Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium
From Ambrx Biopharma Inc.
Via Business Wire
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
From Ambrx, Inc.
Via Business Wire
Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update
From Ambrx, Inc.
Via Business Wire
Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment
Photo by Dimitri Karastelev on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, strives to discover new treatments for mental and neurological... 
Via Benzinga
Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO
From Ambrx, Inc.
Via Business Wire
Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
From Ambrx, Inc.
Via Business Wire
Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
From Ambrx
Via Business Wire
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
These 3 New Biotechs Have Differentiated Platforms, Technology: BofA
Following the expiry of IPO quiet periods for the recently listed Ambrx Biopharma Inc. (NASDAQ: 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
54 Biggest Movers From Yesterday
Gainers Sight Sciences, Inc. (NASDAQ: SGHT) shares jumped 39.6% to settle at $33.50 on Thursday as the company priced its IPO at $24 per share. Cinedigm Corp. (NASDAQ: CIDM)... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.